CDMO Recipharm has entered into an agreement with Swedish life science company OnDosis for the formulation development of a treatment for attention deficit hyperactivity disorder (ADHD) in the U.S. market.
Although there is no cure for ADHD, currently available treatments may help reduce symptoms and improve functioning, according to the National Institute of Mental Health (NIMH). ADHD is commonly treated with medication, education or training, therapy, or a combination of treatments.
Researchers at NIMH, the National Institutes of Health, and across the U.S. are studying the causes of ADHD and suggest that a number of factors may contribute to ADHD, including:
- Genes
- Cigarette smoking, alcohol use, or drug use during pregnancy
- Exposure to environmental toxins, such as high levels of lead, at a young age
- Low birth weight
- Brain injuries
The new treatment for the management of ADHD will be developed by Recipharm’s Centre of Excellence in Oral Solids and will leverage OnDosis’ proprietary technology that integrates oral drugs in form of micro units and individualized dosing, in a handheld device. The advantages are simplified titration, more accurate dosing, and the ability to track dosing and treatment results.
“The global ADHD market amounts to just over $10 billion and there is strong demand for new solutions to help better manage this condition that affects a broad patient population,” Bernard Pluta, president, development services, at Recipharm said, adding that Recipharm’s capabilities in drug formulation using coated pellets in Pessac, France, will be “very valuable assets” in the partnership efforts.
OnDosis, a spin-off from AstraZeneca, is headquartered in Gothenburg, Sweden.
(Source: Recipharm AB)
